FDA Approves Umbralisib (Ukoniq) for Two Lymphomas FDA Approves Umbralisib (Ukoniq) for Two Lymphomas

The new drug has been granted an accelerated approval for use in patients with refractory or relapsed marginal zone lymphoma and follicular lymphoma.FDA Approvals
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news